SD Biosensor, First Participation in JP Morgan Healthcare... "Announcing New Growth Engines and M&A Strategy"

[Asia Economy Reporter Lee Gwan-joo] SD Biosensor announced on the 26th that it will participate in the 'JP Morgan Healthcare Conference' held in San Francisco, USA, from the 9th to the 12th of next month (local time).

Marking its 41st year, the JP Morgan Healthcare Conference is the largest industry event where global bio and pharmaceutical companies and investors gather in one place. Due to the COVID-19 pandemic, the event was held virtually since last year but will resume offline this time.

This is SD Biosensor's first participation in the JP Morgan Healthcare Conference. SD Biosensor was officially invited by JP Morgan and will present at the Asia-Pacific & Latin America (APAC & LatAm) section on the 10th of next month.

During the corporate presentation, Hye-im Cho, Executive Director of SD Biosensor, will present the vision for advancing as a global biotech company, including new growth engines, business synergies with Meridian Bioscience, and future mergers and acquisitions (M&A) strategies.

In particular, she plans to highlight the synergy effects in distribution, production, and portfolio expansion with Meridian Bioscience, whose acquisition was decided last July and is currently in the final stages, signaling SD Biosensor’s full-scale activities in the U.S. market.

Baek Soon-cheol, Manager of the IR team at SD Biosensor, stated, "Given the high level of interest in our future business, this will be an opportunity to communicate SD Biosensor’s vision through numerous one-on-one meetings."

This content was produced with the assistance of AI translation services.